Background. Seasonal influenza causes >200 000 annual hospitalizations in the United States. Current antiviral treatment options are limited to oral or inhaled agents. There is an urgent unmet need for intravenous antiviral treatments.
The morbidity and mortality from seasonal influenza depends on the virulence of and overall immunity to influenza virus subtype(s) in circulation. An estimated mean average of >25 000 deaths and >200 000 hospitalizations occur annually in the United States [1, 2] . The emergence of novel influenza strains, such as pandemic A/H1N1 in 2009 and avian influenza A/H7N9 in 2013, can significantly increase hospitalization and death rates, underscoring the continuing threat to human health of influenza A viruses [3] [4] [5] [6] [7] [8] [9] . Antiviral treatment options for hospitalized patients with influenza are limited to oral or inhaled products. Although observational studies suggest benefits, [10] efficacy has not been demonstrated in formal clinical trials in this setting. Approval of current treatments was based on trials in acute uncomplicated influenza [11] [12] [13] [14] [15] , and end points for influenza antivirals in hospital settings have not been established [16] .
Peramivir is an intravenous neuraminidase inhibitor (NAI) approved in Japan, South Korea and China to treat influenza. Peramivir has potent in vitro activity against influenza A and B viruses, including the novel H7N9 strain [17] [18] [19] . In randomized controlled trials (RCTs) in uncomplicated influenza, peramivir was safe and well tolerated, with clinical efficacy and antiviral activity superior to placebo and similar to oseltamivir [20] [21] [22] [23] . Peramivir was well tolerated in children [24] . Peramivir was used to treat critically ill patients during the 2009 pandemic under a Food and Drug Administration (FDA) emergency use authorization [25] [26] [27] .
This phase 3 study was designed to assess the clinical efficacy and safety of intravenous peramivir given for 5 days in subjects with influenza who required hospitalization and had been symptomatic for <72 hours. As a placebo-controlled design was considered unacceptable, patients received the institutional standard of care (SOC) plus randomized study drug, either placebo or intravenous peramivir.
METHODS

Design
This double blind RCT (NCT00958776), was initiated at 323 hospitals in 21 countries and conducted between September 2009 and November 2012. The study protocol was approved by independent ethics committees or institutional review boards at each site and by national regulatory authorities. An independent data monitoring committee assessed safety at the end of each influenza season and reviewed efficacy data at a preplanned interim analysis.
Subjects
All subjects provided written informed consent. Eligible subjects were male or nonpregnant female ( pregnant women were eligible in the United States) adults, adolescents, or children (aged 6-11 years) with positive influenza rapid antigen test results who met the clinical inclusion criteria (Table 1) . Major exclusions included hospitalization >24 hours at screening, prior NAI or adamantane treatment, or confirmed bacterial infection.
Study Treatments
Subjects were randomized 2:1 to receive intravenous peramivir (BioCryst Pharmaceuticals) or placebo once daily for 5 days. Children and adolescents received peramivir at a dosage of 10 mg/kg once daily, to a maximum of 600 mg per day. Peramivir doses were lowered to 150 or 100 mg once daily in subjects with creatinine clearance of 30-49 or 10-29 mL/min/1.73 m 2 ,
respectively. The study drug was added to the institution's SOC influenza treatment. Randomization was stratified by duration of illness (≤48 vs >48-72 hours), SOC treatment (NAI vs non-NAI vs no antiviral therapy), influenza subtype (influenza A vs B vs not determined), and intensive care unit (ICU) admission status at randomization.
Clinical Assessments
Clinical assessments were measured at screening/baseline and during treatment, as defined in Table 2 .
Virology Assessments
Mucosal secretions were collected and analyzed, as described elsewhere [23] , at screening/baseline, every 12 hours for 108 hours after initiation of treatment, and at day 10. Influenza type/subtype was determined with reversetranscription polymerase chain reaction (RT-PCR). Change in influenza virus titer from baseline was analyzed by means of Heart rate >110/min in children; >100/min in adolescents and adults Systolic blood pressure <80 mm Hg in children; <90 mm Hg in adolescents and adults ≥1 respiratory symptom for <72 h Cough, sore throat, or nasal congestion ≥1 constitutional symptom for <72 h Headache, myalgia, feverishness, or fatigue ≥1 risk factor Illness severity that in the investigator's opinion justified hospitalization; age ≥60 y; presence of COPD or other chronic lung disease requiring daily pharmacotherapy; current history of congestive heart failure or angina; presence of diabetes mellitus, clinically stable or unstable; transcutaneous oxygen saturation <94% (without supplemental oxygen for ≥5 min), or a medically significant decrease in oxygen saturation from an established baseline; history of chronic renal impairment not requiring peritoneal dialysis; serum creatinine >2.0 mg/dL or >177 μmol/L.
Abbreviation: COPD, chronic obstructive pulmonary disease. a Children were defined as subjects aged 6-11 years, adolescents as those aged 12-11 years, and adults as those aged ≥18 years.
viral culture and RT-PCR, using all posttreatment specimens. In vitro susceptibility to NAIs was assessed with neuraminidase enzyme assays [28] for first and last available virus isolates from individual patients. Neuraminidase and hemagglutinin genes were sequenced from viruses isolated from subjects with persistent viral shedding at day 5 or a peramivir median inhibitory concentration >3 times the baseline median of the study population and from a random sample of subjects.
Pharmacokinetics
Plasma peramivir concentrations were measured before and 30 minutes after dosing on days 1 and 5 and, in available specimens, before dosing on days 3 and 4 and at multiple time points after dosing on day 5, as described elsewhere [29] .
Safety Assessments
Safety was evaluated by assessing adverse events and routine hematological and chemistry results.
Statistical Analysis
The intent-to-treat infected (ITTI) population, used to assess baseline characteristics, included all randomized subjects with confirmed influenza who received ≥1 dose of study treatment. The statistical analysis plan specified the non-NAI SOC population (subjects in the ITTI population who did not receive a NAI as part of the SOC) as the primary efficacy analysis population.
The primary end point of time to clinical resolution (TTCR), defined as the time from initiation of study treatment until resolution of ≥4 of 5 vital sign abnormalities for 24 hours (Table 2) , with normalization of temperature and oxygen saturation [30] , was estimated with the Kaplan-Meier method. Sample size calculations were based on results of a previous study [23] in which peramivir-treated subjects matching the inclusion criteria for this study showed a median TTCR of 24.3 hours. Assuming that peramivir added to non-NAI SOC would improve the TTCR by ≥18 hours compared with SOC alone, a sample size of 160 in the non-NAI SOC group was found to have 90% power to detect a hazard ratio of 0.57, using a log-rank statistic and a significance level of .049 (SAS software; version 9.1.3). A multiple regression analysis was performed for the primary efficacy non-NAI SOC population, examining potential effects of baseline characteristics on the primary efficacy end point. Univariate Cox regression models were constructed for each combination of TTCR and relevant independent variables to ascertain important factors for consideration in the multiple regression model. A forward selection method was used to choose the final predictive multiple Cox regression model; a 10% significance level was required to add a new variable into the model. For colinear factors, the best-fitting univariate factor was considered for inclusion in the multiple regression model.
Secondary end points included changes in influenza virus titer within 48 hours (median tissue culture infective dose and quantitative RT-PCR) and number of subjects shedding virus. Secondary clinical end points included time to hospital discharge, incidence of influenza-related complications, incidence and duration of ICU admission during treatment, and Subject-rated influenza symptoms Symptom severity (cough, sore throat, nasal congestion, myalgia, headache, feverishness, and fatigue) rated on 4-point scale twice daily through day 9, once daily through day 13
All symptoms resolved to 0 (absent) or 1 (mild)
Ability to perform daily activities Subject completed visual analog scale (0-10) once daily through day 14
Daily activity score of 10 Daily activity score of 10 a Children were defined as subjects aged 6-11 years, adolescents as those aged 12-11 years, and adults as those aged ≥18 years.
survival. Subject-rated end points included times to symptom alleviation and to resumption of usual activities.
For time-to-event analyses, differences between the KaplanMeier curves for each treated group were assessed using the Wilcoxon-Gehan statistic. For changes in virus titer, differences between groups were evaluated using the van Elteren test. The Cochran-Mantel-Haenszel General Association test was used for binary end points. All analyses of efficacy were stratified by the randomization variables.
Given challenges in identifying patients not receiving an NAI as part of the SOC, an interim analysis of the primary efficacy end point was planned after approximately 70% of subjects were enrolled in the primary analysis population to determine adequacy of the sample size using a conditional power calculation [31, 32] . A maximum sample size of 320 was set, which if exceeded would render the study futile because of the impracticality of recruiting a larger study.
RESULTS
Subject Disposition and Baseline Characteristics
More than 1600 subjects were screened, of whom 405 were randomized ( Figure 1 ). Of 398 randomized subjects who received ≥1 dose of study drug, influenza could not be confirmed in 43, and 17 were excluded from efficacy analyses because of good clinical practice violations at 2 sites. The remaining 338 subjects made up the ITTI population, with 121 in the non-NAI SOC ITTI primary analysis population. The other 217 subjects constituted a separate ITTI NAI SOC population (216 received oseltamivir, and 1 received zanamivir). Subjects were enrolled (23) 19 (24) 9 (12) 22 (15) from 86 (27%) of 323 sites, with 6% of sites enrolling 65% of the subjects. Most enrollment (71%) occurred during Northern hemisphere influenza seasons (Table 3) . India and Eastern European countries contributed the majority of subjects in the primary analysis non-NAI SOC ITTI population (Table 4) . Treatment groups within the non-NAI SOC and NAI SOC populations were well balanced, with no important differences in baseline characteristics (Table 3) . Some important differences were noted between the non-NAI and NAI SOC populations. Of these, lower mean body mass index (24.7 vs 29.1 kg/m 2 )
and lower influenza vaccination rate (5% vs 23%) in the non-NAI SOC group probably reflected underlying demographic differences between subjects from India and Eastern Europe. More subjects in the non-NAI SOC group were admitted to the ICU at baseline (19% vs 9%), but this difference seemed to reflect cultural differences in ICU admission thresholds; 41% of subjects in India were admitted to the ICU, with milder illness compared with ICU subjects elsewhere. Other differences were noted: non-NAI SOC subjects had shorter symptom duration (32% vs 48% symptoms >48 hours), and were less likely to smoke (13% vs 23%), have abnormal chest radiographs at baseline (27% vs 45%), require supplemental oxygen (26% vs 36%), or have measurable virus titers at baseline (31% vs 50%). No differences were noted in the pattern of risk factors requiring hospitalization between the non-NAI and NAI SOC groups. Table 5 shows the effect of peramivir on TTCR at the interim analysis. Peramivir-treated subjects in the non-NAI SOC population showed a modest improvement compared with subjects receiving SOC alone (42.5 vs 49.5 hours), but this difference was not statistically significant (P = .97). Similar results were observed in the NAI SOC population ( peramivir vs placebo, 41.8 vs 48.9 hours; P = .74). In subjects enrolled within 48 hours of symptom onset or admitted to the ICU at baseline, the effect of peramivir seemed more pronounced (42.9 vs 58.2 and 31.5 vs 50.2 hours, respectively). Based on these results, a recalculated sample size indicated that >320 subjects would be required to show a statistically significant difference. The study was terminated for futility following a recommendation of the data monitoring committee.
Clinical Assessments
Component analysis of TTCR indicated that time to resolution of fever was its key driver (Figure 2) , consistent with findings of a prior phase 2 study [23] . Post hoc univariate and multiple regression modeling to assess the effect of baseline characteristics on the primary end point showed that enrollment in regions other than India (Eastern Europe [P < .001] and United States/Canada [P = .001]), duration of illness ≤48 hours (P = .001), female sex (P = .008), oxygen saturation <94% (P = .01), and no history of chronic obstructive pulmonary disease (COPD; P = .03) were associated with longer TTCR (Table 6 ). Of these, desaturation would probably be most directly related to more severe illness; further analyses showed that supplemental oxygen use and need for ICU admission at baseline were associated with longer TTCRs (P = .002) (Figure 3) .
No statistically significant differences among secondary clinical end points were observed between the peramivir and placebo non-NAI SOC treatment groups (Table 7) . Although subjects receiving peramivir experienced a 1-day improvement in time to resumption of usual activities, this difference was not statistically significant (P = .75).
Virology
In the non-NAI SOC group at baseline, virus was detected with culture in 38 subjects and with PCR in 95 ( Table 8 ). The change in virus titer from baseline to 48 hours was −2.25 vs −1.38 log 10 median tissue culture infective dose per milliliter ( peramivir plus SOC vs SOC only; P = .29). Greater reductions in virus shedding were observed in peramivir-treated subjects at key time points, as measured with culture and PCR, but these differences were not statistically significant. All pretreatment virus isolates tested from the ITTI population were sensitive to peramivir and approved NAIs (Table 9) , except for a single A/2009 H1N1 isolate harboring a preexisting H275Y NA mutation. In 1 subject with influenza A/2009 H1N1 infection receiving 600 mg per day of peramivir, a treatmentemergent H275Y mutation was detected at study day 6, with a shift in peramivir median inhibitory concentration from 0.37 to 38.6 nmol/L.
Pharmacokinetics
The observed exposure after intravenous peramivir (600 mg once daily) was consistent with previous reports in patients with influenza [33] . The median predose plasma peramivir level was 96.9 ng/mL in 165 subjects with normal renal function; in a subset of 19 subjects with a full pharmacokinetic profile, geometric mean maximum concentration (C max ) was 30 798 ng/mL, and area under the curve (AUC 0-last ) was 83 729 ng · h/mL.
Safety
The proportion of subjects with adverse events or clinically significant laboratory toxic effects was similar between treatment groups (Table 10) . Events assessed as drug related were also reported at similar rates for peramivir and SOC-only groups. The majority of reported events (55%) were rated as mild or moderate. The majority of 28 serious adverse events were related to underlying influenza infection. The most frequently reported serious adverse events were COPD and pneumonia (in 4 subjects each, 2 in each treatment group). Only 2 subjects were withdrawn from the study owing to adverse events (tachycardia in 1, acute respiratory distress syndrome in 1). The only events reported in ≥5% of subjects were gastrointestinal and occurred at similar rates in both treatment groups. Four subjects died during the study, of whom 3 had received placebo. Causes of In the ITTI non-NAI SOC population, oseltamivir was administered during the study to 5 subjects (12%) in the placebo plus SOC group and 3 (4%) in the peramivir plus SOC group; peramivir was given at a dosage of 600 mg once daily. c In the ITTI NAI SOC population, oseltamivir was administered to 72 subjects (99%) in the placebo plus SOC group and 136 (94%) in the peramivir (600 mg once daily) plus SOC group; in this group, rimantadine was administered to 2 subjects (3%) and amantadine to 1 (1%). d P = .97 (based on the Wilcoxon-Gehan statistic, stratified by duration of illness at randomization, ICU status at baseline, use of supplemental oxygen at baseline, influenza season, and influenza type). e P = .74 (based on the Wilcoxon-Gehan statistic, stratified by duration of illness at randomization, ICU status at baseline, use of supplemental oxygen at baseline, influenza season, and influenza type). death included acute respiratory distress syndrome, multiorgan disorder, and septic shock, all consistent with influenza complications.
DISCUSSION
This study of intravenous peramivir represents the largest documented RCT of an influenza antiviral treatment in hospitalized patients to date. The study was terminated for futility after a planned interim analysis, because the sample size required to maintain power exceeded a predefined boundary based on practical considerations for feasible total sample size. The increased usage of NAIs as SOC in the hospital setting created severe challenges to adequate patient enrollment in the non-NAI SOC group. No significant differences were observed between the 2 treatment groups in the primary analysis population receiving no NAI as part of the SOC or in the overall population. These results may have been affected by dilution of treatment effect owing to the broad spectrum of severity of illness in the patients enrolled. Trends in TTCR favored peramivir in subjects with symptom onset <48 hours and those who required The TTCR is the number of hours from initiation of study treatment until 4 of the 5 signs of clinical resolution (including both temperature and transcutaneous oxygen saturation) met resolution criteria for ≥24 hours. The P value is based on the Wilcoxon-Gehan statistic testing for differences in the TTCR curves for the different ICU admission and supplemental oxygen use strata. Curves are based on Kaplan-Meier estimates. b Time to alleviation of symptoms is the number of hours from initiation of study drug until the start of the time period in which all 7 symptoms of influenza were either absent or present at a level no greater than mild for ≥24 hours. c Time to resolution of fever is the number of hours from initiation of study treatment until temperature was ≤37.2°C (≤99°F) oral or ≤37.8°C (≤100°F) rectal or tympanic for ≥24 hours. d Time to resumption of usual activities is the number of days from initiation of study treatment until the subject was able to resume usual activities. Subjects who did not resume usual activities were censored at their last nonmissing assessment. For this variable, n = 42 n = 74 for the 2 populations. e For this variable, n = 42 n = 72 for the 2 populations.
ICU admission. Albeit not reaching statistical significance, decreases in viral shedding were greater during the first 2 days in peramivir-treated subjects. Overall, intravenous peramivir at 600 mg once daily was safe and well tolerated in this hospitalized population. The incidence and severity of adverse events and laboratory abnormalities were similar for placebo and peramivir and consistent with those expected for a population of hospitalized patients with influenza. Very few subjects discontinued the study owing to adverse events. These results illustrate the challenges in conducting clinical studies in hospitalized influenza and highlight factors confounding study design and demonstration of a treatment effect for antivirals in hospitalized influenza. The study was conducted in >300 clinical sites in 21 countries worldwide during 6 influenza seasons. Subject enrollment was not evenly distributed; 6% of sites enrolled 63% of the subjects, and 237 of 323 sites enrolled no subjects.
Many factors predispose patients with seasonal influenza to serious illness, including underlying chronic cardiovascular, respiratory, renal, or neurological disease; immune compromise; pregnancy; infancy or advanced age; and diabetes. There is no generally accepted case definition for hospitalized influenza for the purposes of interventional clinical research. Patients with influenza may receive hospital care for diverse reasons, including dehydration, primary viral pneumonia, secondary bacterial pneumonia, organ or systemic failure, or exacerbation of an underlying chronic illness. The contribution of ongoing influenza viral proliferation to subsequent clinical course under these diverse situations will vary substantially. There are also large regional differences in hospital admission criteria, with some hospitals admitting patients who might have been treated and sent home in other regions. All of these factors complicate the ability to evaluate treatment effects. Many observational studies have reported morbidity and mortality benefits from the early use of oseltamivir in hospitalized patients (reviewed in [34] ). Although approval of oseltamivir was based on studies in uncomplicated outpatient influenza, and there are no placebo-controlled studies of oseltamivir in hospitalized patients, its use in hospitalized patients is recommended by the US Centers for Disease Control and Prevention. The SOC use of oseltamivir for hospitalized influenza represents a technically untested comparator with the same mechanism of action as intravenous NAIs, creating a profound challenge in trial design for influenza studies in hospitalized patients that cannot easily be addressed.
The study was designed after widespread consultation with influenza experts, and followed FDA guidance on the development of drugs for the treatment of influenza [35] . Regulatory guidance in the United States recommends that sponsors consider randomized dose-response, dose-duration, or superiority SOC add-on trial designs in hospitalized patients but includes no guidance on end points other than that the design should allow demonstration of effect of the drug on improving patients' clinical status. The primary efficacy end point for this study was TTCR, a composite comprising normalization of vital signs and oxygen saturation based on studies of community-acquired pneumonia [30] and evaluated in a phase 2 study of intravenous peramivir [23] . Although primary and secondary end points of this study were designed to meet FDA guidelines, no end points have been validated in this patient population. The TTCR may have only a weak relationship with viral replication. End points such as change in influenza viral titer or duration of fever have strong relationships with viral replication, but their correlation with clinical outcomes in hospitalized patients may be influenced by underlying comorbid conditions or complications of influenza that progress independently of viral proliferation, such as secondary bacterial infection or systemic inflammatory response syndrome, or by the various therapies for these complications. The challenges in conducting RCTs in hospitalized patients with influenza emphasize the importance of postmarketing observational studies in demonstrating the utility of antiviral drugs in this setting [10] .
No antiviral treatment has been approved for the treatment of influenza in hospitalized patients; nonetheless, the need remains for an intravenous influenza antiviral drug. Study BCX1812-301 did not meet its primary or secondary efficacy end points. However, based on the challenges outlined above, it would be inappropriate to conclude that intravenous peramivir was ineffective in hospitalized patients with influenza. In contrast to this study's findings, a placebo-controlled trial in uncomplicated outpatients showed a benefit for a single infusion of peramivir, similar to that achieved with 5 days of oseltamivir [20] . Currently, the only viable regulatory pathway for approval of influenza antivirals seems to be placebo-controlled studies in acute uncomplicated influenza. 
Notes
